Resource Center
In this episode we feature a recent White Paper and our CMV T Cell immunity panel. (See the featured resource following. This episode discusses CMV cell mediated immunity and the recently released white paper evaluating various methodologies, including Eurofins Viracor’s CMV T Cell Immunity Panel.
This bi-lateral lung transplant recipient is a 65 year-old male patient who received his lung transplant due to end-stage lung disease secondary to non-CF bronchiectasis. The donor and recipient CMV serostatus is D+/R+. The patient’s initial peri-operative course was complicated by difficult explant, primary graft dysfunction, respiratory failure requiring prolonged mechanical ventilation, renal insufficiency and recurrent infectious concerns, including pseudomonas and stenotrophomonas pneumonias.